Immunovant (IMVT) Projected to Post Quarterly Earnings on Friday

Immunovant (NASDAQ:IMVT) will likely be releasing its Q3 2026 results before the market opens on Friday, February 6th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter. Individuals may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Friday, February 6, 2026 at 8:00 AM ET.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.01). During the same period in the previous year, the company earned ($0.74) EPS. On average, analysts expect Immunovant to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunovant Trading Up 1.5%

IMVT opened at $26.45 on Friday. Immunovant has a 1-year low of $12.72 and a 1-year high of $27.80. The firm has a 50-day moving average price of $25.36 and a two-hundred day moving average price of $20.43. The stock has a market capitalization of $4.64 billion, a PE ratio of -9.31 and a beta of 0.57.

Analysts Set New Price Targets

IMVT has been the subject of a number of analyst reports. Truist Financial boosted their price objective on shares of Immunovant from $16.00 to $22.00 and gave the company a “hold” rating in a report on Thursday, January 8th. Wolfe Research upgraded Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 price objective for the company in a research report on Tuesday, January 6th. Guggenheim reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Immunovant in a research report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunovant in a report on Friday, January 9th. Finally, The Goldman Sachs Group boosted their price target on Immunovant from $18.00 to $28.00 and gave the company a “neutral” rating in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunovant presently has an average rating of “Moderate Buy” and an average price target of $30.78.

Insider Buying and Selling

In related news, Director Andrew J. Fromkin sold 22,249 shares of Immunovant stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $23.25, for a total transaction of $517,289.25. Following the completion of the sale, the director directly owned 85,852 shares of the company’s stock, valued at approximately $1,996,059. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Melanie Gloria sold 12,626 shares of Immunovant stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $23.62, for a total value of $298,226.12. Following the sale, the chief operating officer directly owned 173,511 shares of the company’s stock, valued at $4,098,329.82. This represents a 6.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 63,868 shares of company stock valued at $1,538,470 in the last ninety days. 1.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Immunovant

Hedge funds have recently bought and sold shares of the company. Prelude Capital Management LLC bought a new stake in shares of Immunovant in the third quarter worth $672,000. Algert Global LLC bought a new position in Immunovant during the 3rd quarter worth $563,000. Creative Planning increased its stake in shares of Immunovant by 8.9% in the third quarter. Creative Planning now owns 38,503 shares of the company’s stock valued at $621,000 after buying an additional 3,135 shares during the period. LMR Partners LLP bought a new position in shares of Immunovant during the second quarter worth about $401,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Immunovant by 4.1% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,641 shares of the company’s stock worth $683,000 after acquiring an additional 1,670 shares during the period. 47.08% of the stock is owned by institutional investors.

Immunovant Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.